Regeneron Pharmaceuticals, Inc. (REGN)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for REGN is $859.53, 8.7% above the last close of $790.74 on Oct 16, 2026; targets range from $758.91 to $1,023.04. Rating consensus: Buy.
Snapshot
- P/E19.6x
- P/E vs sector-30.5%
- P/E vs own+18.0%
- Target upside+8.7%
- ConsensusBuy
- Market cap$81.41B
- FCF yield+4.3%
- Insiders-$6.51M
- Earnings in14d
- News
Why it moved
Regeneron Pharmaceuticals, Inc. (REGN) fell 0.7% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
2 stories on the day (30-day average 1.4).
- Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
- 2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $790.74 · +39.6% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50Death 10d ago
- RSI57
- Support-2.2%
- Resistance+1.5%
- Off 52w high-7.2%
- Off ATH-33.6%
- 52w range$790.74
- Bollingerupper half
- MACD5.82
- ATR+2.8%
- Volume0.9x
Analyst price targets
24 firms with a target in the last 12 months · last close $790.74 · as of Oct 16, 2026
Strong buy 4 · Buy 15 · Hold 9 · Sell 0 · Strong sell 1
Revenue and free cash flow
Q2 FY2026: Revenue +16.7% year over year, free cash flow 7.8% of revenue, operating margin 33.1%.
| Q2 FY2026 | Jun 30, 2026 | $4.29B | 12.20 | $334M | 86.6% | 33.1% | 30.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.61B | 6.75 | $848M | 81.4% | 17.8% | 20.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.88B | 7.86 | $922M | 84.9% | 22.7% | 21.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.75B | 13.62 | $1.42B | 86.1% | 27.3% | 38.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.68B | 12.81 | $968M | 85.6% | 29.4% | 37.9% |
| Q1 FY2025 | Mar 31, 2025 | $3.03B | 7.27 | $774M | 84.7% | 19.5% | 26.7% |
| Q4 FY2024 | Dec 31, 2024 | $3.79B | 8.06 | $996M | 85.1% | 26.1% | 24.2% |
| Q3 FY2024 | Sep 30, 2024 | $3.72B | 11.54 | $1.11B | 86.8% | 31.7% | 36.0% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $499.74 | -1.8% | -10.4% | +14.0% | 29.1 | $127B | |
| 2 |  | $428.26 | 0.0% | 0.0% | +1.9% | 19.0 | $92.88B | |
| 3 |  | $218.01 | -7.8% | -7.8% | -25.0% | — | $87.04B | |
| 4 | | $790.74 | -0.7% | -7.2% | +8.7% | 19.6 | $81.41B | |
| 5 |  | $302.30 | +1.2% | -0.2% | +10.9% | 12.5 | $79.88B | |
| 6 |  | $231.83 | -0.9% | -52.8% | +61.5% | 39.2 | $31.02B | |
| 7 |  | $113.07 | -0.2% | -13.0% | +13.6% | 14.4 | $22.92B | |
| 8 |  | $72.57 | +0.1% | -0.1% | -7.0% | 62.6 | $11.38B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.